The patents represent the first issued for a family of applications focused in brachytherapy, said Cianna.
According to the company, the Savi multi-catheter open architecture design allows for the delivery of patient-specific radiation that minimizes the radiation dose to healthy tissue. For appropriate patients, Savi is an advanced technology that may reduce treatment time to just five days, versus six to eight weeks for traditional radiation therapy.
Jill Anderson, president and CEO of Cianna Medical, said: “These two patents are the first of many we expect to secure through our comprehensive intellectual property portfolio.
“We are well positioned to protect our products and our leadership in the breast brachytherapy market. Strong IP and innovative technology make accelerated partial beast irradiation with Savi a viable therapy for women suffering from breast cancer.”